TLPPF Financials: Telix Pharmaceuticals Limited AI Analysis



Financials

TLPPF Financial

Telix Pharmaceuticals Limited

$10.25

At close: Aug 06, 16:00:00 GMT-4

$10.25

Post-market: Aug 06, 18:49:11 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$10.25

Open

$10.41

Day's Range

$10.25 - $10.41

52 week range

$5.91 - $12.5

Volume

100

Avg.Volume

3.2K

Dividend yield

EPS (TTM)

-0.02

Market Cap

$3.4B

What is Telix Pharmaceutical Ltd.?

Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 1,120 full-time employees. The company went IPO on 2017-11-15. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

Features

Markets

News

Breakdown	TTM	12/31/2025	06/30/2025	12/31/2024	06/30/2024	12/31/2023
Revenue	803	413	390	276	239	281
Revenue Growth (YoY)	56%	50%	63%	-2%	9%	107%
Cost of Revenue	421	221	200	106	90	108
Gross Profit	381	192	189	170	148	173
Selling, General & Admin	192	95	96	70	58	167
Research & Development	171	89	81	72	55	98
Operating Expenses	350	170	180	148	116	150
Other Non Operating Income (Expenses)	-27	-14	-12	-14	-5	-7
Pretax Income	-5	0	-4	15	22	15
Income Tax Expense	1	4	-2	0	3	-4
Net Income	-7	-4	-2	14	19	19
Net Income Growth	-121%	-129%	-111%	-26%	-236%	-158%
Shares Outstanding (Diluted)	338.55	338.55	337.2	362.64	327.72	329.79
Shares Change (YoY)	-7%	-7%	3%	10%	3%	5%
EPS (Diluted)	-0.02	-0.01	0	0.03	0.05	0.05
EPS Growth	-121%	-137%	-111%	-34%	-233%	-156%
Free Cash Flow	-73	-62	-10	-12	9	2
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	47.44%	46.48%	48.46%	61.59%	61.92%	61.56%
Operating Margin	3.73%	5.08%	2.3%	7.6%	13.38%	7.82%
Profit Margin	-0.87%	-0.96%	-0.51%	5.07%	7.94%	6.76%
Free Cash Flow Margin	-9.09%	-15.01%	-2.56%	-4.34%	3.76%	0.71%
EBITDA	--	--	--	--	--	25
EBITDA Margin	--	--	--	--	--	8.89%
D&A For EBITDA	--	--	--	--	--	3
EBIT	30	21	9	21	32	22
EBIT Margin	3.73%	5.08%	2.3%	7.6%	13.38%	7.82%
Effective Tax Rate	-20%	0%	50%	0%	13.63%	-26.66%

Breakdown

TTM

12/31/2025

06/30/2025

12/31/2024

06/30/2024

12/31/2023

Revenue

803

413

390

276

239

281

Revenue Growth (YoY)

56%

50%

63%

-2%

107%

Cost of Revenue

421

221

200

106

108

Gross Profit

381

192

189

170

148

173

Selling, General & Admin

192

167

Research & Development

171

Operating Expenses

350

170

180

148

116

150

Other Non Operating Income (Expenses)

-27

-14

-12

-14

-5

-7

Pretax Income

-5

-4

Income Tax Expense

-2

-4

Net Income

-7

-4

-2

Net Income Growth

-121%

-129%

-111%

-26%

-236%

-158%

Shares Outstanding (Diluted)

338.55

337.2

362.64

327.72

329.79

Shares Change (YoY)

-7%

10%

EPS (Diluted)

-0.02

-0.01

0.03

0.05

EPS Growth

-121%

-137%

-111%

-34%

-233%

-156%

Free Cash Flow

-73

-62

-10

-12

Free Cash Flow Per Share

Gross Margin

47.44%

46.48%

48.46%

61.59%

61.92%

61.56%

Operating Margin

3.73%

5.08%

2.3%

7.6%

13.38%

7.82%

Profit Margin

-0.87%

-0.96%

-0.51%

5.07%

7.94%

6.76%

Free Cash Flow Margin

-9.09%

-15.01%

-2.56%

-4.34%

3.76%

0.71%

EBITDA

EBITDA Margin

8.89%

D&A For EBITDA

EBIT

EBIT Margin

3.73%

5.08%

2.3%

7.6%

13.38%

7.82%

Effective Tax Rate

-20%

50%

13.63%

-26.66%

Follow-Up Questions

What are Telix Pharmaceuticals Limited's key financial statements?



According to the latest financial statement (Form-10K), Telix Pharmaceuticals Limited has a total asset of $0, Net loss of $0

What are the key financial ratios for TLPPF?



Telix Pharmaceuticals Limited's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Telix Pharmaceuticals Limited's revenue broken down by segment or geography?



Telix Pharmaceuticals Limited largest revenue segment is Precision Medicine, at a revenue of 771,106,000 in the most earnings release.For geography, United States is the primary market for Telix Pharmaceuticals Limited, at a revenue of 762,308,000.

Is Telix Pharmaceuticals Limited profitable?



no, according to the latest financial statements, Telix Pharmaceuticals Limited has a net loss of $0

Does Telix Pharmaceuticals Limited have any liabilities?



no, Telix Pharmaceuticals Limited has liability of 0

How many outstanding shares for Telix Pharmaceuticals Limited?



Telix Pharmaceuticals Limited has a total outstanding shares of 0

Telix Pharmaceuticals Limited (TLPPF) Financial

TLPPF Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Telix Pharmaceutical Ltd.?

Telix Pharmaceuticals Limited (TLPPF) Financial

TLPPF Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Telix Pharmaceutical Ltd.?

TLPPF Income

Follow-Up Questions

What are Telix Pharmaceuticals Limited's key financial statements?

What are the key financial ratios for TLPPF?

How is Telix Pharmaceuticals Limited's revenue broken down by segment or geography?

Is Telix Pharmaceuticals Limited profitable?

Does Telix Pharmaceuticals Limited have any liabilities?

How many outstanding shares for Telix Pharmaceuticals Limited?